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Background and objective 
Prior small-scale clinical trials showed that Artemisia annua and Artemisia afra infusions, decoctions, 
capsules, or tablets were low cost, easy to use, and efficient in curing malaria infections. In a larger-scale 
trial in Kalima district, Democratic Republic of Congo, we aimed to show A. annua and/or A. afra 
infusions were superior or at least equivalent to artesunate-amodiaquine (ASAQ) against malaria.  
 
Methods  
A double blind, randomized clinical trial with 957 malaria-infected patients had two treatment arms: 472 
patients for ASAQ and 471 for Artemisia (248 A. annua, 223 A. afra) remained at end of the trial. ASAQ-
treated patients were treated per manufacturer posology, and Artemisia-treated patients received 
1L/day of dry leaf/twig infusions for 7 days; both arms had 28-day follow-up. Parasitemia and 




Artemisinin content of A. afra was negligible, but therapeutic responses of patients were similar to A. 
annua-treated patients; trophozoites cleared after 24h, but took up to 14 days to clear in ASAQ-treated 
patients. D28 cure rates defined as absence of parasitemia were for pediatrics 82, 91, and 50% for A. 
afra, A. annua and ASAQ; while for adults cure rates were 91, 100, and 30%, respectively. Fever 
clearance took 48h for ASAQ, but 24h for Artemisia. From D14-28 no Artemisia-treated patients had 
detectable gametocytes, while 10 ASAQ-treated patients remained gametocyte carriers at D28. More 
females than males were gametocyte carriers in the ASAQ arm but unaffected in the Artemisia arms. 
Hemoglobin remained constant at 11g/dL for A. afra after D1, while for A. annua and ASAQ it decreased 
to 9-9.5g/dL. Only 5.0% of Artemisia-treated patients reported adverse effects, vs. 42.8% for ASAQ.  
 
Conclusion  
A. annua and A. afra infusions are polytherapies with better outcomes than ASAQ against malaria. In 
contrast to ASAQ, both Artemisias appeared to break the cycle of malaria by eliminating gametocytes. 
This study merits further investigation for possible inclusion of Artemisia tea infusions as an alternative 
for fighting and eradicating malaria. 
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The Democratic Republic of Congo (DRC) has one of the highest malaria rates. In 2016 >50,000 people 
died, mainly children (WHO, 2017 http://apps.who.int/iris/bitstream/10665/259492/1/9789241565523-
eng.pdf). Maniema province is a holo-endemic zone with >80% of the population infected (Programme 
National de Lutte contre le Paludisme, 2015. Rapport Malaria. Kinshasa, RDC; PNLP). In 2005, 
Artemisinin Combination Therapy (ACT) became the first line treatment for all in the DRC.  
Artemisia annua L. and Artemisia afra Jacq. ex Willd., of Chinese and South African origin, respectively, 
were used for centuries medicinally as infusions or powders to treat malaria (Willcox et al., 2004; 
Weathers et al., 2014; Liu et al., 2010). Both showed in vitro efficacy against Plasmodium falciparum 
(Kraft et al., 2003; Moyo et al., 2016; Gathirwa et al., 2007; Liu et al., 2010). For generations, A. afra was 
an integral part of the pharmacopeia in many regions of DRC and other areas of eastern and southern 
Africa (FAO Forestry paper 67: 68-73, Rome. http://www.fao.org/docrep/015/an797e/an797e00.pdf). In 
recent case studies, administration of dried A. annua leaf tablets successfully cured 18 patients with 
severe malaria who did not respond to therapy with ACT (artemether-lumefantrine) and i.v. artesunate 
(Daddy et al., 2017).  
Medicinal plants represent the main, if not the only treatment accessible to much of humanity (WHO, 
2014  http://www.who.int/medicines/publications/traditional/trm_strategy14_23/en/) and may offer a 
low cost and potentially more widely available alternative to ACTs. A. annua is grown in commercial 
plantations and by small stake-holder farmers in at least 39 countries, 33 of which are in Africa 
(Supplemental Material). For traditional medicine, WHO provided guidelines (WHO, 2000 
http://apps.who.int/iris/bitstream/10665/66783/1/WHO_EDM_TRM_2000.1.pdf) and encouraged 
studies and clinical trials on herbal medicines (WHO, 2014). Subsequently, we launched a large-scale 
clinical trial aimed at confirming encouraging results from smaller-scale trials in Africa and South 
America with A. annua and A. absinthium. In those small trials cure rates of >95% were reported 
(Mueller et al., 2000; Gebeyaw et al., 2010; Chougouo et al., 2012; Zime-Diawara et al., 2015).  
Methods 
Plant material, handling and phytochemical analysis. 
Field-grown leaves and twigs of Artemisia annua L. and Artemisia afra Jacq. ex Willd. (Asteraceae) were 
collected in France (PAR), Senegal (SEN), Burundi (BUR), and Luxembourg (LUX) and processed as 
described in Munyangi et al. (2018) where voucher ids also are listed.  Artemisinin was measured using 
gas chromatography mass spectroscopy (GCMS) instead of HPLC to avoid artemisinin false positives 
(Smith et al. 2010). Extraction and assay methods for phytochemical compounds are detailed in 
Munyangi et al. (2018) where phytochemical contents of both Artemisia sp. are documented: A. annua 
had 1.34-1.70 mg artemisinin/g dry weight; A. afra had 0.036 mg artemisinin/g dry weight.   
Study design 
The study was done in 2015 in Kalima health district, Pangi zone, Maniema province, in five areas: 
Kakutya, Kinkungwa, Kamundala, Lubile, and Kakozwa (for location map see supplemental material of 
Munyangi et al. 2018). Patients with uncomplicated malaria were enrolled in the three arms of the trial 
(Figure 1) October to December 2015. The research protocol was registered and approved by the 














DRC Ministry of Health. All adult patients provided written consent to participate in the trial; minor 
patients were signed by parents. The study followed guidelines of the Declaration of Helsinki and Tokyo 
for humans. 
Criteria for inclusion of patients 
Patients were recruited by passive case finding. Eligibility of patients was restricted to adults or children 
≥5 yr with axillary temperature of ≥37.5°C and parasitemia of 2,000-200,000 trophozoites/μL. Patients 
with these symptoms were excluded: severe malaria, undernourishment, repetitive vomiting ± diarrhea, 
other concomitant infectious disease, known allergy to ACTs, pregnancy or breast feeding, cardiac, 
hepatic, or renal deficiencies. We also excluded patients treated with antimalarial drugs within 7d 
preceding the trial or with antibiotics that might have antimalarial effects. Patients were enrolled and 
distributed randomly into a treatment arm (Figure 1). Demographics of the study group are in Table 1. 
Drugs were distributed in numbered opaque envelopes selected randomly by each patient. Clinical 
symptoms of enrolled patients are shown in Table S1. 
Clinical and laboratory analyses 
According to WHO procedures, a rapid diagnostic test (RDT) confirmed malarial infection. Kalima health 
district is a sentinel surveillance zone for malaria, so SDBioline® Malaria Ag P.f./Pan test (batch nr 
05FK60) was used on D0 for all patients. Thin and thick blood smears also were microscopically analyzed 
for trophozoites and gametocytes. Trophozoites were measured per μL of blood; gametocytes were 
noted as present or absent to determine number of carriers. In each trial area, slides were scrutinized by 
two independent laboratories. In case of dubious or conflicting results, a PNLP expert was consulted. A 
random 10% of slides collected at different stages of the trial were quality-control checked by a third 
party. Hemoglobin level, asexual parasites, and presence of gametocytes were measured on D0. 
Hemoglobin was measured spectrophotometrically at 540nm using Drabkin’s Reagent at the peripheral 
health centers. Hemoglobin was also measured at the reference laboratory via hemoglobin analyzer; to 
settle value discrepancies, the reference lab value was used. After testing, patients were administered 
their first drug dose and a capillary blood sample was collected, dried on Whatman grade 3 filter paper, 
and stored for eventual genotyping. Patient follow-up including thick and thin blood smears was at days 
1, 2, 3, 4, 7, 14, 21, and 28 post trial enrollment. From D0-D7, patients were treated in hospital to insure 
therapeutic compliance. Alanine (ALAT) and aspartate (ASAT) liver transaminases also were measured 
using the method of Reitman and Frankel (1957). 
Drug administration  
Artesunate-amodiaquine (ASAQ Winthrop, Sanofi-Aventis) was administered as tablets 25mg/67.5mg, 
50mg/135mg, and 100mg/270mg. Manufacturer posology was: 4mg of artesunate and 10mg of 
amodiaquine/kg, once daily for 3 days, followed by ASAQ placebo tablets for the remaining 4 days. In 
the Artemisia arm, patients drank 0.33L of A. annua or A. afra infusion every 8h for 7d. Infusion 
preparation was: 5g of dried leaves and twigs of A. annua or A. afra to 1L of boiling water, infuse for 
10min, and filter through sterilized 1mm mesh. Pediatrics and adults received the same amount of 
Artemisia tea infusion; there was no adjustment for body weight. 
The trial was double blinded as detailed in Munyangi et al. (2018). Briefly, A. annua and A. afra arms 














3 followed by ASAQ placebo on D4, 5, 6, and 7; these same patients also received Artemisia placebo 
from D1-7. ASAQ placebo consisted of pill-shaped saccharose/glucose tablets purchased in a pharmacy. 
To conceive a placebo for Artemisia infusion was more challenging. WHO suggested using the drug at 
very low dose, so A. annua and A. afra placebos contained 0.2g/L of plant material and patients drank 
placebo infusion of one Artemisia species or the other. All trial personnel were unaware of arm 
assignments. 
All treatments were administered inside health facilities and under medical control. In case of vomiting 
30min post-administration, the same drug was re-administered. For vomiting 60min post-
administration, no new administration took place. In case of persistent vomiting, the patient was 
excluded from the trial and their infection separately treated. Adverse events were recorded and 
defined by clinical observations and patient self-reporting. 
Concomitant treatment.  
Medical treatment that did not violate trial exclusion criteria was maintained for patients having a 
known disease other than malaria at the beginning of the trial.  
Management and statistical analysis of data 
All data were initially recorded by hand in clinic notebooks, then transferred to an Excel file. Proportions 
were compared using chi-square test or Fisher exact test. Continuous and normally distributed data 
were compared by analysis of variance (ANOVA) and Student’s t-Test. Other non-normally distributed 
data were compared by Mann-Whitney U-test. Survival analyses, fever clearance time, and the parasite 
clearance time used the Kaplan-Meier method with two-sided log-rank statistics. No significant 
differences were seen among the five sites, so the data were pooled. Data were analyzed using SPSS for 
Windows version 1.0.0.903 and R for Windows version 3.4.2. P-values <0.05 were considered 
statistically significant.   
 
Results and Discussion 
This trial was conducted as a superiority trial. Where equivalence was noted, it was so stated. The 
primary outcome of the trial was that, based on microscopic analyses, both Artemisia sp. cured malaria 
faster and more effectively than ASAQ. The secondary outcomes were that compared to ASAQ, 
Artemisia-treated patients also had microscopically undetectable gametocytes and fewer adverse side 
effects. 
Clinical Admission Characteristics: There were 943 patients who completed the trial with 258 pediatrics 
in each of the ASAQ and A. annua arms (Table 1). The median age was 29 yrs in the ASAQ group, 19 yrs 
in the A. annua group and 25 yrs in the A. afra group (Table 2); ages within each group ranged from 6-50 
yr. Of these, 67.7% were male, 32.3% were female; 41.1% were pediatrics and 58.9% adults in the A. 
annua group.  In the A. afra group, 70.9% were male, 29.1% were female; 22.9% were pediatrics and 
77.1% adults. In the ASAQ group, 65.3% were males, 34.7% were female; 22.3% were pediatrics and 
77.7% adults. Of the five study sites, three included all three treatment arms, one had A. annua and 
ASAQ; the other had A. afra and ASAQ (Table 2).  At admission parasitemia was > 33,000 














Fever and parasitemia progression: Cures rates were established by D28 parasitemia. Compared to 
ASAQ-treated patients with an overall 34.3% cure by D28, A. afra and A. annua -treated patients were 
88.8 and 96.4% cured, respectively (Table 3). Cures for ASAQ-treated patients were 49.5% for pediatrics 
(ages 5-15 yr) and 30.0% for adults (ages 16-65) (Table 3).  Pediatric cures for A. annua and A. afra-
treated patients were 91.2 and 82.4%, respectively, while for adults, cures were 100 and 90.7%, 
respectively (Table 3). There were 344 patients with parasites at D28; 9 for A. annua, 25 for A. afra, and 
310 for ASAQ. Due to degradation of stored blood samples, we were unable to conduct a valid PCR 
analysis of the D28 patients with parasitemia. Considering the large number of D28 patients with 
parasitemia, a thorough PCR analysis is needed in future studies. 
Fever clearance took 24h in the Artemisia arm and 48h for ASAQ (Figure 2). Zime-Diawara et al. (2015) 
noticed total apyrexia even faster, only 12h post-first Artemisia infusion. Using the long-rank test, p 
values were all significantly different among all four measured groups: both Artemisias vs. ASAQ; A. 
annua vs. A. afra; A. annua vs. ASAQ, A. afra vs. ASAQ.  
On D1, parasitemia decreased 97.7% in the Artemisia arm and 85.2% for ASAQ. In both Artemisia arms, 
parasitemia totally cleared on D2 (Figure 3). In the ASAQ arm, however, parasites remained in some 
patients until D14. By the log-rank test at D28, three of the four compared groups were significantly 
different, but there was no significant difference between A. annua and A. afra (p=0.505). These results 
are similar to Zime-Diawara et al. (2015) with 108 patients receiving 1L/d of 12g/L A. annua infusion. 
Parasitemia disappeared in all patients after 36h, with excellent clinical tolerance. In a similar 48-patient 
study, Mueller et al. (2004) observed trophozoite disappearance by D4 for 92% of patients. Our 
Artemisia-treated patients were 96.4% cured on D28; only 5% of patients showed side effects, which 
was significantly better than ASAQ-treated patients with 42.8% adverse side effects (Table 4).  
Patients treated with ASAQs received weight-adjusted amounts of artesunate ranging from 147.2 to 
1,293 mg in toto. Patients treated with A. afra received a maximum amount of artemisinin of 1.26mg, 
while those treated with A. annua received 46.9mg (BUR) or 59.5mg (LUX) in toto; there was no weight 
adjustment. This was 3-1,000 fold less artemisinin vs. ASAQs, yet Artemisia therapeutic outcome was 
better. This was consistent with recent case studies (Daddy et al., 2017) demonstrating efficacy of A. 
annua compressed leaf tablets (DLA) in treating patients unresponsive to either ASAQ or i.v. artesunate. 
The treatment course of DLA used in that study provided 55mg maximum artemisinin to adults; for 
pediatrics, it was as low as 13.75mg. These results collectively suggest other phytochemicals in the 
plants were crucial to the potent therapeutic outcome of the Artemisias.  
Gametocyte elimination: D0 gametocyte carriers present in ASAQ-treated patients declined beginning 
on D7 post-treatment; by D28 only 10 of 472 patients were carriers (Figure 4). In contrast, no 
gametocyte carriers were detectable in either Artemisia treatment from D14 onwards suggesting that 
both Artemisias, but not ASAQ, eliminated gametocytes. Gametocyte carriage was completely 
eliminated in all age groups treated with Artemisia (Table 5). In ASAQ-treated patients, both pediatric 
and adult patients still had microscopically detectable gametocytes at D28 (Table 5). Microscopic 
analysis underestimates gametocyte counts by several fold (Babiker and Schneider 2008), so future 
studies should use nested PCR to further probe for the presence of gametocytes in Artemisia-treated 
patients.  
Gender differences occurred in the ASAQ group. There were 326 males in the Artemisia arm and 308 in 














responded equally well to Artemisia, there was significantly more gametocyte carriage in females than 
males in the ASAQ-treated arm for D14-28 (Fisher’s Exact test, p=0.012; data not shown). There was no 
differential age response in females. Artemisia-treated male carriers were significantly different at D2-4 
but not at D7-28. Overall, these results indicated that Artemisias were better than ASAQ at removing 
gametocytes in females.    
Hemoglobin improvement by A. afra, but not ASAQ or A. annua: While hemoglobin at D0, 1, 3, and 4 
between A. annua and ASAQ was not statistically different (post hoc test, p>0.05), between A. annua 
and A. afra there was a significant difference (Figure 5). Hemoglobin remained significantly greater at 
about 11g/dL post treatment for A. afra vs. ~9 and 9.5g/dL for ASAQ and A. annua, respectively. This 
similarity between ASAQ and A. annua is likely the result of artemisinin, known to reduce hemoglobin 
during treatment (Kurth et al., 2016). A. afra has but a trace of artemisinin (see Table 1 in Munyangi et 
al. (2018) for artemisinin content of each Artemisia sp. treatment) and thus, as expected, there was no 
decline in hemoglobin. 
ALAT and ASAT were not altered: Although liver transaminases are often altered in malaria patients 
(Woodford et al., 2018), there were no significant differences observed in ALAT and ASAT among the 
three treatment arms (see supplemental Figure S1).   
Other studies using Artemisia tea infusions: In China the traditional treatment against malaria is a daily 
dose from 4.5 to 9g of dry leaves and twigs of A. annua infused in boiling water. In 1972, the Institute for 
Traditional Medicine of Beijing treated 31 patients with an ether extract; 20 had P. vivax infection, 9 had 
P. falciparum, and 2 patients had both. Fever cleared in 36h for the P. falciparum-infected patients 
(Zhang 2005; Cui and Su 2009). In another instance, Chang and But (1986) administered 72g of A. annua 
in an alcoholic extract over 3 days on 485 patients infected with P. falciparum, and on 105 patients with 
P. vivax. The cure rate was 100 % against both malaria species. In 2000, Mueller et al. (2000) treated 53 
DRC patients infected with P. falciparum using two different treatments: infusion and decoction. The 
posology was 5g of dried leaves in 1L over 5d. The average cure rate was 92 % after 4 days of treatment. 
In Ethiopia, Gebeyaw et al. (2010) treated 73 patients suffering from uncomplicated malaria with 1L of 
A. annua dried leaf infusion using 5g/L per day over 7d; 95.5% of patients were cured without adverse 
effects. Chougouo-Kengne et al. (2012) compared A. annua infusion with artesunate alone or combined 
with amodiaquine on 73 patients suffering from uncomplicated falciparum malaria. The posology was 5g 
of dried leaf infusion in boiling water, over 5 or 7d. The 7d treatment improved the results from 71.3% 
to 100%, without any side effects. Overall, 7d of treatment with 5g/L Artemisia annua infusion seemed 
to provide the best therapeutic outcome. 
Synergistic effects: In prior tea infusion studies, there was efficacy of the A. annua infusion against 
uncomplicated malaria without significant side effects. This is in line with our results showing a cure rate 
of 99.5% on D28 for Artemisia with only 5% side effects. Previously, artemisinin was considered the only 
active molecule, so prior studies tried to reach high levels in their preparations. Artemisinin is only 
present in traces in some Artemisia varieties and usually absent in A. afra. This of course raises the 
question of the role of artemisinin in these infusions used to treat malaria. A. annua and A. afra contain 
hundreds of phytochemical molecules and minerals. Antimalarial activity has been demonstrated for 
some 20 of these as summarized in the review by Weathers et al. (2014). It is important to note in that 














et al., 2018), yet all patients treated with that species had the same therapeutic response as those 
treated with A. annua.  
Artemisinin drug resistance: Despite the fact that A. annua shows high efficacy without side effects, 
there has been reluctance in endorsing use of the plant. Low artemisinin content of the plant elicited 
concerns that this might induce artemisinin drug resistance (Blanke et al., 2008; Mueller et al., 2004; 
WHO, 2012 http://www.who.int/malaria/position_statement_herbal_remedy_artemisia_annua_l.pdf). 
Since then rodent studies using per os dried leaf Artemisia (DLA), Elfawal et al. (2015) demonstrated that 
compared to pure artemisinin, DLA was threefold more resilient against evolution of artemisinin drug 
resistance. Furthermore, DLA even eliminated artemisinin-resistant parasites in a P. yoelli rodent model 
(Elfawal et al., 2015). In humans unresponsive to either ASAQ or i.v. artesunate, A. annua (DLA) 
eliminated parasites within a few days even in comatose pediatrics (Daddy et al., 2017). Studies showed 
that the numerous phytochemicals in A. annua and A. afra provide synergies and multiple interactions, 
likely constituting a polytherapy against malaria (Elford et al., 1987; Li et al., 2018; Liu et al., 1992; 
Suberu et al., 2013). Together, those data and this study indicate that artemisinin is not the sole 
phytochemical demonstrating antimalarial efficacy by Artemisia sp. Moreover, the presence of multiple 
phytochemicals in Artemisia sp. acts not as a mono or dual therapy, but as a poly-combination-therapy. 
In the present study, we saw a large number of ASAQ failures, yet in the same localities, A. afra and 
especially A. annua were highly effective. If those failures are ASAQ resistance, then Artemisia tea 
infusions cured those patients. As we and others observe mounting failures of ACTs in Africa, Artemisia 
annua in particular could provide an effective and rapid alternative for holding the parasite at bay. For 
how long? No one knows, but lives are at risk and this is an inexpensive, safe and effective therapeutic 
that could be implemented rather quickly. 
 
Conclusions 
Treating uncomplicated malaria with either A. annua or A. afra was superior to the artesunate-
amodiaquine ASAQ treatment. Fever and parasitemia clearances were faster and more efficient with 
both Artemisia species than with ASAQ; adverse effects were negligible. At D14-28 gametocyte carriage 
was undetectable in Artemisia-treated patients, so transmission to the mosquito should be interrupted. 
Artemisia is a polytherapy with at least 10 active molecules likely acting in synergy, so resistance is 
therefore unlikely to emerge. Plants can be grown and used by local populations, which could help 
counteract the problems caused by fake or obsolete antimalarial drugs. Despite these exciting results, 
however, it is important that further large-scale studies be launched to optimize use of these plants and 
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Figure 2. Average fever progression among the three treatment arms. Top, graphical representation. 
Bottom, Kaplan–Meier; survival time of fever started when a patient was included in the study (Day 0). 
Patients were followed until Day 28. For patients withdrawing from the study before Day 28 or still 
having fever until Day 28, survival time is said to be censored. The survival probability was calculated 
using the Kaplan–Meier method.  The censored rates of A. annua, A. afra, and ASAQ are 0.0%, 10.3%, 































Figure 3. Average parasitemia progression among the three treatment arms. Top, graphical 
representation. Bottom, Kaplan–Meier; survival time of parasites started when a patient was included in 
the study (Day 0). Patients were followed until Day 28. For patients withdrawing from the study before 
Day 28 or still having parasites until Day 28, survival time is said to be censored. The censored survival 







































Figure 5. Hemoglobin levels during the first four days of treatment. 
 
Table 1: Demographics of the Artemisia and ASAQ trial arms at time of enrollment (D0). 
Treatment arm Gender Age 
  Male (%) Female (%) ≤ 5 yrs 6-15 yrs (%) > 15 yrs (%) 
A. annua 168 (67.7%) 80 (32.3%) 0 102 (41.1%) 146 (58.9%) 
A. afra 158 (70.9%) 65 (29.1%) 0 51 (22.9%) 172 (77.1%) 








Site average patient age (yr) 
Kakutya Kinkungwa Kamundala Lubile Kakozwa 
A. annua 19 22 25 24 nm 20 
A. afra 25 28 27.5 nm 26.5 13.5 
ASAQ 29 33 29.5 32 23 21 
Overall 26 26 28.5 28 25 19.5 














A. annua 42,426 40,632 36,120 ≥ 50,0001 nm ≥ 50,0001 
A. afra 33,911 39,860 39,150 nm 29,617 ≥ 50,0001 
ASAQ 43,018 38,702 42,106 ≥ 50,0001 39,915 ≥ 50,0001 
                                                                % Parasites D28 Mean/site (trophozoites/µL) 
A. annua na 
 91% = 0  
9% ≤10 
100% = 0 100% = 0 nm 100% = 0 
A. afra na 100% = 0  100% ≤102 nm 100% = 0 
92% = 0  
8% ≤10 
ASAQ2 na 
 93% = 0 
7% ≤10 
6% = 0 
84% ≤10  
10%  ≥10,000 
100% ≤10 100% = 0 
38% ≤10  
62% ≥10,000 
Not all test sites included both Artemisias; na, not applicable; nm, not measured at that site.  
1 Parasites were not enumerated beyond 50,000.  


























1 N, total number within age group less any who left the trial; n, number with 0 parasitemia.  
2 (%), n/N x 100. 
  
Table 3. Cure rates by age group within each trial arm at Days 14 and 28. 




































































subjects in the 
Artemisia arms 
Number of 
subjects in the 
ASAQ arm 
Abdominal pain 0 25 
Asthenia 0 30 
Diarrhea 0 5 
Drowsiness 0 3 
Fatty cough 0 1 
Hypoglycemia 0 20 
Insomnia 0 10 
Nausea 10 30 
Pruritis 0 35 
Vertigo 0 1 
Vomiting 15 50 
TOTAL 25 210 







Graph abstract tea trial 
Table 5. Level of microscopically determined gametocyte carriage decrease D14-28 within age groups. 
Age (yrs) A. annua n/N (%) A. afra n/N (%) ASAQ n/N (%) 
Children (5-15) 43/43 (100%) 102/102 (100%) 111/114 (97.4%) 
Adults (16-65) 205/205 (100%) 147/147 (100%) 369/376 (98.1%) 
Total 248/248 (100%) 249/249 (100%) 480/490 (98.0%) 
N, total within age group; n, number of patients with microscopically undetectable gametocytes. 
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